㈜셀레믹스

Publications

Celemics’ Publications

First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-2 positive gastric cancer with sequential genomic profiling

-

First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-2 positive gastric cancer with sequential genomic profiling

Chung HC, Bang YJ, S Fuchs C, Qin SK, Satoh T, Shitara K, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol. 17(5):491–501.

 

10.21203/rs.3.rs-254208/v1